In recent years, RNA interference (RNAi) has emerged as a promising strategy for gene-specific therapies, especially in targeting cancer-driving genes. Despite this potential, RNAi’s path to clinical application has been fraught with obstacles such as poor cellular uptake, rapid immune clearance, and the challenge of crossing the blood-brain barrier (BBB) to target brain tumors effectively. Now, a groundbreaking approach led by Professors Fan Kelong and Yan Xiyun at the Institute of Biophysics, Chinese Academy of Sciences, is poised to overcome these barriers and push the boundaries of cancer treatment.
The team has pioneered a ferritin-based system to deliver small interfering RNA (siRNA) directly to glioblastoma (GBM) cells. Ferritin, a naturally occurring protein usually involved in iron storage, was re-engineered into a specialized variant named tHFn(+). This design includes positively charged surfaces and a modified C-terminal, optimized to disintegrate in the mildly acidic environment typically found within a cell’s endosomes. As the ferritin shell disassembles, the siRNA cargo is released and bypasses lysosomal degradation, entering the cytoplasm where it can exert its therapeutic effects.
Critical to their research was the use of cryo-electron microscopy, which allowed the team to observe and confirm how the ferritin structure responded to pH changes. This responsiveness is crucial for ensuring the effective release and action of siRNA within the target cells.
The experimental results of this novel system have been highly encouraging. The engineered tHFn(+) variant effectively delivered siRNA to cells, leading to pronounced gene knockdown demonstrated in vitro. More remarkably, in vivo studies in animal models showed that this delivery system could cross the BBB and accurately target GBM cells. Delivery of siRNA targeted against genes such as siTERT and siEGFR resulted in significant therapeutic effects in mouse models.
Beyond highlighting a potential breakthrough in tackling glioblastoma, this ferritin-based platform could pave the way for broader RNAi therapeutic applications. Its ability to facilitate controlled siRNA release and efficient delivery positions it as a promising tool not only for cancer treatment but potentially for various genetic disorders.
Key Takeaways:
- The ferritin-based siRNA delivery system represents a significant advancement in glioblastoma treatment strategies, a notoriously aggressive brain cancer.
- This technology shows potential in overcoming major RNAi therapy barriers, such as enhancing cellular uptake and crossing the BBB efficiently.
- Beyond glioblastoma, the versatility of this system opens new possibilities for RNAi therapies in diverse clinical contexts, potentially revolutionizing treatments for a range of genetic conditions.